scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1011949884 |
P356 | DOI | 10.1007/S13311-012-0147-4 |
P8608 | Fatcat ID | release_pkmodsdxsffhnmbr5lw5v5p3dq |
P3181 | OpenCitations bibliographic resource ID | 3887981 |
P932 | PMC publication ID | 3557356 |
P698 | PubMed publication ID | 23055048 |
P2093 | author name string | Bibiana Bielekova | |
P2860 | cites work | Daclizumab for relapsing remitting multiple sclerosis | Q24200496 |
Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor | Q24312136 | ||
Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting | Q24318910 | ||
Structural basis for NKG2A/CD94 recognition of HLA-E. | Q24336854 | ||
A humanized antibody that binds to the interleukin 2 receptor | Q24600912 | ||
Natural killer cells and autoimmunity | Q24793284 | ||
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells | Q28214975 | ||
Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors | Q28282381 | ||
Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment | Q28587823 | ||
Risk alleles for multiple sclerosis identified by a genomewide study | Q29614890 | ||
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration | Q33194554 | ||
NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis | Q33381309 | ||
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production | Q33396971 | ||
Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. | Q33854381 | ||
Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death | Q33876302 | ||
Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. | Q34088526 | ||
The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. | Q34152180 | ||
NK cells and NKT cells in innate defense against viral infections | Q34332682 | ||
The biology of human natural killer-cell subsets | Q34430869 | ||
Control of T-cell activation by CD4+ CD25+ suppressor T cells | Q34448423 | ||
Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells | Q34501407 | ||
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta | Q34514715 | ||
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. | Q34596171 | ||
CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes | Q34596186 | ||
Monoclonal antibodies in MS: mechanisms of action | Q34615261 | ||
The IL-2/IL-15 receptor systems: targets for immunotherapy | Q34630134 | ||
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results | Q34665233 | ||
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells | Q34893862 | ||
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy | Q34949098 | ||
Human NK cells and their receptors. | Q35035740 | ||
Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis | Q35091437 | ||
The main function of IL-2 is to promote the development of T regulatory cells | Q35213797 | ||
Intrathecal effects of daclizumab treatment of multiple sclerosis | Q35635127 | ||
Unraveling human natural killer cell deficiency | Q35780328 | ||
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors | Q36351101 | ||
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial | Q36397083 | ||
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization | Q36402763 | ||
Lymphoid neogenesis in chronic inflammatory diseases. | Q36405080 | ||
Search for organising principles: understanding in systems biology | Q36628523 | ||
Maternal acceptance of the fetus: true human tolerance | Q36752550 | ||
Human natural killer cells | Q36787596 | ||
IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells. | Q36992146 | ||
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. | Q37159538 | ||
CD25 as an immune regulatory molecule expressed on myeloid dendritic cells | Q37300261 | ||
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells | Q37313533 | ||
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. | Q37343849 | ||
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis | Q37354974 | ||
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 | ||
Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses | Q37712459 | ||
Lymphoid tissue inducer cells: innate cells critical for CD4+ T cell memory responses? | Q37977138 | ||
Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac | Q39168921 | ||
Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors | Q39577528 | ||
IL-2 receptors in adult T-cell leukemia: a target for immunotherapy | Q39601718 | ||
Functional and morphologic characterization of human T cells continuously grown in vitro | Q39818384 | ||
Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response | Q41472662 | ||
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells | Q41475516 | ||
Interleukin-2, interleukin-15, and their receptors | Q41722182 | ||
Cutting edge: lymphoid tissue inducer cells maintain memory CD4 T cells within secondary lymphoid tissue | Q42325266 | ||
Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis | Q43539775 | ||
The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytes | Q44493843 | ||
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta | Q44597307 | ||
Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. | Q45840886 | ||
IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis | Q46106529 | ||
Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. | Q46211971 | ||
Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood | Q46655432 | ||
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials | Q47242957 | ||
Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. | Q47871733 | ||
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosis | Q48491256 | ||
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis | Q48949792 | ||
A role for natural killer cells in the immunopathogenesis of multiple sclerosis. | Q50876710 | ||
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. | Q55044269 | ||
CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity | Q57265370 | ||
Lineage Relationship Analysis of RORγt+Innate Lymphoid Cells | Q57520258 | ||
Immune responses in interleukin-2-deficient mice | Q58194363 | ||
Accumulation of CD16−CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua | Q67700611 | ||
The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75) | Q68097686 | ||
Cytokine production by CD16–CD56bright natural killer cells in the human early pregnancy decidua | Q72085502 | ||
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta | Q72287439 | ||
Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor | Q72609371 | ||
Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events | Q73370304 | ||
Human IL-2 receptor alpha chain deficiency | Q73952904 | ||
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells | Q74602353 | ||
Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children | Q74617252 | ||
The use of antibodies against the IL-2 receptor in transplantation | Q77485579 | ||
Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group | Q78106881 | ||
Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers | Q78404451 | ||
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment | Q78409843 | ||
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody | Q80896193 | ||
CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation | Q80967934 | ||
The structure of interleukin-2 complexed with its alpha receptor | Q81810296 | ||
Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation | Q84488242 | ||
Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis | Q84565920 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple sclerosis | Q8277 |
P304 | page(s) | 55-67 | |
P577 | publication date | 2013-01-01 | |
P1433 | published in | Neurotherapeutics | Q15716631 |
P1476 | title | Daclizumab therapy for multiple sclerosis | |
P478 | volume | 10 |
Q38397484 | A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. |
Q37502636 | Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis |
Q50871333 | Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials. |
Q36691970 | Cutaneous adverse events in multiple sclerosis patients treated with daclizumab |
Q37136498 | Cytokine Therapies in Neurological Disease |
Q47959279 | Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis. |
Q38604207 | Daclizumab for the treatment of multiple sclerosis |
Q39175716 | Daclizumab for the treatment of relapsing-remitting multiple sclerosis |
Q33589947 | Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis |
Q35619174 | Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis |
Q43905322 | Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis |
Q37657070 | Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis |
Q39140303 | Daclizumab: A Review in Relapsing Multiple Sclerosis |
Q39434495 | Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis |
Q64106331 | Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis |
Q37558843 | Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis |
Q38315992 | Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs |
Q52619984 | Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010. |
Q55401140 | Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis. |
Q38837294 | Further understanding of the immunopathology of multiple sclerosis: impact on future treatments |
Q55286986 | Immunosuppressant Peptide Abu-TGIRIS-Abu-NH2 and its Application for Treatment of Multiple Sclerosis. |
Q34356481 | In search of magic bullets: the golden age of immunotherapeutics. |
Q30908652 | Infection risk in patients on multiple sclerosis therapeutics |
Q38144976 | Infectious complications of immune modulatory agents. |
Q38570574 | Innate and adaptive immune responses in the CNS. |
Q38111620 | Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. |
Q38364547 | Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. |
Q38153471 | Multiple sclerosis treatment and infectious issues: update 2013. |
Q41459008 | New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis. |
Q39021942 | Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar. |
Q36521247 | Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination |
Q40962441 | Pharmacodynamic effects of daclizumab in the intrathecal compartment |
Q36585726 | Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis. |
Q37459065 | Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program |
Q37286272 | Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens |
Q93048503 | Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls |
Q27693249 | Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis |
Q36975701 | Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis |
Q38114422 | Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis |
Q35012335 | Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma |
Q90531326 | Spotlight on daclizumab: its potential in the treatment of multiple sclerosis |
Q38291845 | The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®. |
Q90706071 | The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction |
Q30252875 | The effects of interleukin-2 on immune response regulation |
Q30730505 | The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis |
Q38089599 | The role of natural killer cells in multiple sclerosis and their therapeutic implications |
Q45066717 | The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations |
Q37030744 | Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach. |
Search more.